Mizuho lowered the firm’s price target on MiMedx (MDXG) to $12 from $15 and keeps an Outperform rating on the shares following the earnings report. The firm says coverage determination updates are the major catalysts for MiMedx, as “decreased spending on bad actors could confer share donation” to the company despite only 25% selling price exposure in the category.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG: